pravastatin has been researched along with Disease Models, Animal in 137 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 10 (7.30) | 18.2507 |
2000's | 54 (39.42) | 29.6817 |
2010's | 59 (43.07) | 24.3611 |
2020's | 14 (10.22) | 2.80 |
Authors | Studies |
---|---|
Hori, S; Kikkawa, T; Mori, S; Ohtsuki, S; Otagiri, M; Takanaga, H; Terasaki, T | 1 |
Askew, V; Auerbach, B; Dillon, L; Hanselman, JC; Kennedy, RM; Kowala, MC; Larsen, SD; Lin, Z; Lu, GH; Miller, S; Park, WK; Robertson, A; Roth, BD; Sekerke, C; Song, Y; Steinbaugh, BA; Sun, K; Tait, BD; Trivedi, BK | 1 |
Bienvenu, AL; Picot, S | 1 |
Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
Cao, LP; Li, L; Nie, SN; Ren, Y; Sun, ZR; Wang, MM; Yang, ZZ; Zhang, P; Zhang, W | 1 |
Chen, ZL; Deng, F; Hu, JJ; Li, C; Lin, ZB; Liu, KX; Liu, WF; Liu, Y; Luo, SD; Sun, QS; Yan, ZZ; Yang, X; Yao, ZW; Zhao, BC | 1 |
Cho, SS; Jang, H; Jang, WI; Kim, MJ; Kwak, SY; Lee, SB; Park, S; Shim, S | 1 |
Clifton, RG; Costantine, MM; Saade, GR | 1 |
Adams, LC; Botnar, RM; Brangsch, J; Hamm, B; Kaufmann, JO; Makowski, MR; Onthank, DC; Reimann, C; Robinson, SP; Thöne-Reineke, C | 1 |
Birukov, A; Dechend, R; Geisberger, S; Golic, M; Haase, N; Herse, F; Heuser, A; Kräker, K; Müller, DN; O'Driscoll, JM; Patey, O; Schütte, T; Thilaganathan, B; Verlohren, S | 1 |
Cherrington, NJ; Clarke, JD; Csanaky, IL; Toth, EL | 1 |
Abd Allah, EF; Charan, J; Hashem, A; Jaipal, N; Kashyap, P; Kumar, S; Ram, H; Siddaiah, CN; Singh, BP; Tabassum, B; Tripathi, R | 1 |
Jang, H; Jang, WS; Kim, H; Kim, K; Kim, MJ; Kim, YH; Kwak, SY; Lee, SJ; Myung, JK; Na, J; Park, S; Shim, S | 1 |
Adam, N; Al-Rewashdy, H; Bronicki, LM; Coriati, A; Holcik, M; Jasmin, BJ; Mears, A; Péladeau, C; Renaud, JM; Thabet, M; Vanstone, J | 1 |
Cabral, WA; Collins, FS; Cubria, MB; DuBose, A; Erdos, MR; Kamalapathy, P; Karim, L; Masoudi, A; Nazarian, A; Oftadeh, R; Snyder, BD; Suarez, S | 1 |
Chen, Y; Hu, L; Jia, J; Liu, X; Luo, X; Ou, Y; Shen, W; Shi, H; Sun, S; Zhang, H; Zhou, G | 1 |
Andia, ME; Botnar, RM; Lavin Plaza, B; Lorrio, S; Phinikaridou, A; Potter, M; Rashid, I | 1 |
Abeydeera, D; Demer, LL; Fong, F; Iriana, S; Lu, M; Patel, NR; Qiao, R; Tintut, Y; Xian, JZ | 1 |
Girardi, G | 1 |
Alijotas-Reig, J; Baraldès-Farré, A; Esteve-Valverde, E; Ferrer-Oliveras, R; Gil-Aliberas, N; Llurba, E | 1 |
Chen, J; Li, H; Li, N; Liu, C; Sun, J; Wang, C | 1 |
Huai, J; Wang, GJ; Yang, Z; Yi, YH | 1 |
Beck, B; Donner, D; du Toit, EF; Headrick, JP; Oi, M; Peart, J; Wendt, L | 1 |
Hur, J; Kang, JY; Kim, YK; Lee, SY; Liang, L; Rhee, CK | 1 |
Clark, JE; Garrett, N; Girardi, G; Pombo, J; Simmons, M; Umpierrez, M | 1 |
Li, Q; Xiao, S; Zhang, X | 1 |
Gao, JH; Lu, JL; Wang, HM | 1 |
Chimini, JS; da Silva, MLS; Dias-Junior, CA; Possomato-Vieira, JS | 1 |
Heo, TH; Park, KY | 1 |
Cho, O; Heo, TH; Kim, HS; Park, KY | 1 |
Banek, CT; Bauer, AJ; Capoccia, S; Gilbert, JS; Gillham, H; Needham, K; Regal, JF | 1 |
Fukumoto, Y; Kudo, S; Liao, JK; Minami, T; Nochioka, K; Shiba, N; Shimokawa, H; Takai, Y; Tanaka, S; Williams, CL | 1 |
Costantine, MM; Hankins, GD; Kechichian, T; Longo, M; Saad, AF; Saade, GR; Sbrana, E; Tamayo, E; Wen, M; Yin, H | 1 |
Albano, A; Aronovitz, M; Galper, JB; Jin, H; Link, MS; Noujaim, SF; Park, HJ; Rajab, M; Welzig, CM; Zhang, Y | 1 |
Carver, AR; Costantine, MM; Hankins, GD; Perez-Polo, JR; Saade, GR; Tamayo, E | 1 |
Costantine, MM; Gamble, P; Hankins, GD; Kechichian, T; Longo, M; McDonnold, M; Saade, GR; Tamayo, E | 1 |
Chen, W; Jiang, Y; Li, P; Lin, N; Lu, C; Xu, Y; Zhang, H; Zhang, Y; Zhu, B | 1 |
Brem, H; Huang, Y; Hwang, L; Jallo, G; Kang, JU; Pradilla, G; Ruzevick, J; Suk, I; Tyler, BM; Wicks, RT; Zhang, K; Zhao, M | 1 |
Aktaş, SG; Atay, A; Çuhadar, S; Dursun, S; Köseoğlu, M | 1 |
Andrikopoulou, M; Burd, I; Carver, AR; Costantine, MM; Gamble, P; Hou, Z; Lei, J; Mori, S; Saade, GR; Tamayo, E; Zhang, J | 1 |
Adamicová, K; Adamkov, M; Bojková, B; Chmelová, M; Kajo, K; Kapinová, A; Kassayová, M; Kružliak, P; Kubatka, P; Orendáš, P; Péč, M; Sadloňová, V; Stollárová, N; Výbohová, D | 1 |
Fledderus, JO; Giles, RH; Gremmels, H; Joles, JA; Oosterhuis, NR; Papazova, DA; van Koppen, A; Verhaar, MC | 1 |
Li, F; Ling, Z; Liu, C; Liu, L; Liu, X; Shu, N; Xu, D; Zhang, M; Zhong, Z | 1 |
Ikeda, S; Kikuchi, N; Kudo, S; Kurosawa, R; Minami, T; Miyata, S; Nogi, M; Omura, J; Satoh, K; Satoh, T; Shimokawa, H; Sunamura, S; Suzuki, K | 1 |
Clark, SM; Costantine, MM; Diken, ZM; Kechichian, TB; Olson, GL; Saad, AF; Saade, GR | 1 |
Chen, Y; Dong, B; Guo, T; Li, P; Liang, WJ; Liu, C; Ma, H; Pang, XY; Shan, MR; Wang, SX; Wang, XQ; Wang, YL; Yin, YL; Yu, HY; Zhou, SN | 1 |
Gruenbaum, Y; Meshorer, E | 1 |
Haslinger-Löffler, B | 1 |
Demachi, J; Fukumoto, Y; Ishii, N; Kagaya, Y; Karibe, A; Nakano, M; Nawata, J; Satoh, K; Shimokawa, H; Sugamura, K; Sugimura, K | 1 |
Canty, JM; Cimato, T; Iyer, V; Suzuki, G | 1 |
Fang, HY; Wu, SY | 1 |
Satoh, A; Satoh, M | 1 |
Baudelin, C; Benderitter, M; Buard, V; Gaugler, MH; Guipaud, O; Holler, V; Milliat, F; Perez, Mdel R; Sache, A; Squiban, C; Tamarat, R | 1 |
Girardi, G; Redecha, P; Torry, D; van Rooijen, N | 1 |
Anantharamaiah, GM; Cao, D; Garber, DW; Handattu, SP; Kadish, I; Li, L; Monroe, CE; Nayyar, G; Palgunachari, MN; van Groen, T | 1 |
Ito, R; Ito, Y; Itoh, T; Kajikuri, J; Watanabe, Y; Yamamoto, T | 1 |
Brahmachari, S; Gendelman, HE; Ghosh, A; Matras, J; Pahan, K; Roy, A | 1 |
Bang, YJ; Byun, HJ; Kim, W; Lee, HS; Lee, SH; Lee, SM; Myung, SJ; Yang, JI; Yoon, JH | 1 |
de Hoz, R; Mendez, T; Ramírez, AI; Ramírez, JM; Raposo, R; Redondo, A; Rojas, B; Salazar, JJ; Tejerina, T; Triviño, A | 1 |
Eldawoody, H; Kimura, N; Nakayama, T; Saito, A; Shimizu, H; Takahashi, A; Tominaga, T | 1 |
Ezaki, K; Hara, M; Nagano-Torigoe, Y; Nakagawa, M; Saikawa, T; Takahashi, N; Teshima, Y; Thuc, LC; Yufu, K | 1 |
Chen, CC; Hsu, YJ; Lee, TM; Lien, HY; Lin, CC; Shih, CM | 1 |
Castellani, LW; Fogelman, AM; Iikuni, N; La Cava, A; Li, H; Lin, Z; Lusis, AJ; Navab, M; Rullo, OJ; Trejo-Lopez, Y; Tsao, BP; Van Dyck, C; Wang, X; Woo, JM; Woo, KM; Wu, H | 1 |
Arruda, AP; Breder, I; Coope, A; de Oliveira, HC; Dorighello, Gde G; Milanski, M; Razolli, D; Velloso, LA | 1 |
Ando, K; Inoue, N; Ishibashi, T; Kamioka, M; Kaneshiro, T; Maruyama, Y; Ohkawara, H; Saitoh, S; Sugimoto, K; Takeishi, Y; Takuwa, Y; Uekita, H | 1 |
Kim, JW; Kim, KH; Kim, SC; Kim, TJ; Kim, YH; Kim, YK; Kwon, SS; Lee, SH; Lee, SY; Rhee, CK; Yoon, HK | 1 |
Chang, CC; Huang, HC; Lee, FY; Lee, JY; Lee, SD; Lin, HC; Wang, SS | 1 |
Ahmed, A; Girardi, G; Khan, Y; Seshan, SV; Singh, J | 1 |
Kückelhaus, CS; Kückelhaus, SA; Muniz-Junqueira, MI | 1 |
Hasuwa, H; Ikawa, M; Kidoya, H; Kimura, T; Kumasawa, K; Morioka, Y; Okabe, M; Saito-Fujita, T; Takakura, N | 1 |
Aubuchon, M; Schulz, LC; Schust, DJ | 1 |
Brcakova, E; Cermanova, J; Fuksa, L; Hirsova, P; Hyspler, R; Kolouchova, G; Lotkova, H; Micuda, S; Sispera, L; Slanarova, M; Tomsik, P | 1 |
Kageji, T; Kanematsu, Y; Kinouchi, T; Kitazato, KT; Matsushita, N; Nagahiro, S; Satomi, J; Shimada, K; Tada, Y; Yagi, K | 1 |
Biasibetti, R; Bobermin, L; Gonçalves, CA; Quincozes-Santos, A; Rodrigues, L; Tramontina, AC; Tramontina, F; Wartchow, KM | 1 |
Chan, CY; Chang, CC; Chuang, CL; Hsin, IF; Huang, HC; Lee, FY; Lee, SD; Lin, HC; Teng, TH; Wang, SS | 1 |
Ahmed, A; Girardi, G; Singh, J | 1 |
Black, A; Byrne, J; Dietz, HC; Hill, AD; Huuskonen, V; Kay, E; Kearney, S; McAllister, H; McGuinness, J; McLoughlin, D; Redmond, JM; Terzo, E | 1 |
Brcakova, E; Cermanova, J; Fuksa, L; Hirsova, P; Kolouchova, G; Lastuvkova, H; Micuda, S; Mokry, J; Nachtigal, P | 1 |
Ishii, Y; Izumikawa, K; Kimura, S; Kohno, S; Ohno, A; Saga, T; Tashiro, M; Tashiro, T; Tateda, K; Yamaguchi, K | 1 |
Bytautiene, E; Costantine, MM; Fox, KA; Hankins, GD; Kechichian, T; Longo, M; Saade, GR; Tamayo, E | 1 |
Hong, SJ; Kim, PS; Ko, JH; Mustoe, TA; Zhao, Y | 1 |
Kumagai, K; Miyata, N; Niwa, M; Nozaki, Y | 1 |
Anastasiou-Nana, M; Andreadou, I; Farmakis, D; Iliodromitis, EK; Kremastinos, DT; Papalois, A; Papapetropoulos, A; Prokovas, E; Sigala, F; Spyridaki, K; Zoga, A | 1 |
Kamata, K; Kobayashi, T; Matsumoto, T; Nemoto, S; Taguchi, K | 1 |
Basraon, SK; Costantine, MM; Hankins, GD; Longo, M; Makhlouf, M; Menon, R; Saade, GR | 1 |
Huang, C; Huang, Z; Jiang, H; Wu, G; Xie, Q; Xu, L | 1 |
Kang, HH; Kim, IK; Kim, JW; Kim, KH; Kim, YK; Kwon, SS; Lee, SH; Lee, SY; Rhee, CK; Yeo, CD | 1 |
Alexander, JS; Bharwani, S; Carter, P; Elrod, JW; Grisham, MB; Harada, H; Joh, T; Jordan, P; Manas, K; Sasaki, M; Warren, A; Wolcott, M | 1 |
Ichihara, K; Kanda, M; Satoh, K | 1 |
Blum, HE; Spangenberg, HC; Thimme, R; Von Weizsäcker, F; Zuber-Jerger, I | 1 |
Domínguez, J; Schultz, M | 1 |
Aiso, M; Akashi, M; Kurihara, H; Sano, N; Sasamoto, T; Tachizawa, H; Takada, Y; Takamori, Y; Takayanagi, M; Takikawa, H | 1 |
Chen, Y; Kiyomoto, H; Kohno, M; Mizushige, K; Ohmori, K; Sato, C; Shinomiya, K; Takeuchi, H; Yu, Y | 1 |
Chang, NC; Chou, TF; Lee, TM; Lin, MS; Tsai, CH | 1 |
Kakinuma, C; Kuwayama, C; Naba, H; Ogihara, T; Ohnishi, S | 1 |
Bouchier-Hayes, D; Casey, RG; Chen, G; Joyce, M; Roche-Nagle, G | 1 |
Cha, JH; Kang, DH; Kang, SW; Kim, J; Kim, YS; Li, C; Lim, SW; Song, JC; Sun, BK; Yang, CW | 1 |
Caracchini, R; Colucci, M; Giannini, S; Gresele, P; Guglielmini, G; Momi, S; Monopoli, A; Ongini, E; Rossiello, MR; Semeraro, N | 1 |
Banno, H; Fujita, H; Kobayashi, M; Komori, K; Kuwano, H; Nakayama, M; Sugimoto, M; Yamanouchi, D | 1 |
Kakinuma, C; Naba, H; Ogihara, T; Ohnishi, S | 1 |
Feng, JH; Kang, MF; Li, YQ; Ma, LP; Nie, DN; Wu, YD; Xie, SF; Xu, LZ; Yin, SM | 1 |
Chen, C; Ran, ZH; Xiao, SD | 1 |
Dichgans, M; Hamann, GF; Trinkl, A; Vosko, MR; Wunderlich, N | 1 |
Abolhassani, F; Ebrahimnejad, M; Jahanzad, I; Nouri, M; Pourabbasi, A | 1 |
Clements, JD; Jamali, F | 1 |
Funauchi, M; Ikoma, S; Kinoshita, K; Nozaki, Y; Sugiyama, M; Yamagata, T | 1 |
Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Lai, ZF; Matsuba, S; Ogawa, H; Tanaka, T; Tokutomi, Y; Yamamoto, E; Yamashita, T | 1 |
Chen, Y; Kohno, M; Kosaka, H; Mizukawa, M; Ohmori, K; Shinomiya, K; Yoshida, J; Zeng, Y; Zhang, L | 1 |
Arakawa, E; Hasegawa, K; Ina, Y; Matsubara, M; Takada, C; Takayama, M; Yao, K | 1 |
Abe, M; Caslake, MJ; Fukuhara, A; Funahashi, T; Kihara, S; Kobayashi, H; Komuro, R; Matsuda, M; McMahon, A; Shepherd, J; Shimomura, I; Takagi, T | 1 |
Arakawa, T; Fujiwara, Y; Higuchi, K; Oshitani, N; Shiba, M; Taira, K; Takeuchi, K; Tanigawa, T; Tominaga, K; Watanabe, T; Yamato, M | 1 |
Chen, B; Zheng, Z | 1 |
Chang, NC; Lee, TM; Lin, MS | 1 |
Arai, M; Bao, N; Fujiwara, H; Fujiwara, T; Iwasa, M; Kawamura, I; Kobayashi, H; Minatoguchi, S; Misao, Y; Nishigaki, K; Sumi, S; Takemura, G; Yamaki, T; Yasuda, S | 1 |
Fujioka, D; Kawabata, K; Kitta, Y; Kobayashi, T; Kodama, Y; Kugiyama, K; Nakamura, T; Obata, JE; Saito, Y; Takano, H; Yano, T | 1 |
Hori, M; Kitagawa, K; Ohyama, N; Sasaki, T; Sugiura, S; Terasaki, Y; Todo, K; Yagita, Y | 1 |
Crockett, JC; Hughes, A; Idris, AI; Rogers, MJ | 1 |
Chiba, M; Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M | 1 |
Akino, M; Matsui, Y; Okamoto, H; Onozuka, H; Tsutsui, H; Xu, Z | 1 |
Kita, T; Otani, H; Tanaka, M; Yokode, M | 1 |
Fujioka, T; Fukami, M; Fukushige, J; Nara, F; Shigehara, E; Shimada, Y; Shimotsu, H; Tsujita, Y | 1 |
Albarrán, OG; García-Robles, R; Rábano, A; Ruilope, LM; Villa, E | 1 |
Dai, E; Liu, LY; Lucas, A; Nation, PN | 1 |
Horikoshi, H; Ito, T; Shiomi, M; Tsujita, Y; Tsukada, T | 1 |
Asanuma, H; Hori, M; Kitakaze, M; Komamura, K; Kuzuya, T; Minamino, T; Sato, H; Takeda, H; Ueda, Y | 1 |
Gross, W; März, W; Müller, HM; Olbrich, HG; Siekmeier, R; Wieland, H | 1 |
Ando, A; Hori, M; Horio, M; Imai, E; Kawada, N; Moriyama, T; Nagatoya, K; Takeji, M | 1 |
Brinkmann, V; Bruns, C; Cottens, S; Hommel, U; Kallen, J; Kamata, T; Takada, Y; Weitz-Schmidt, G; Welzenbach, K | 1 |
Cittadino, M; Coelho, OR; Coelho-Filho, OR; De Luca, IM; Hyslop, S; Moreno Júnior, H; Sampaio, RC; Tanus-Santos, JE | 1 |
Egashira, K; Inoue, S; Kataoka, C; Kitamoto, S; Koyanagi, M; Ni, W; Takeshita, A | 1 |
Enomoto, M; Hirouchi, Y; Ito, T; Shiomi, M | 1 |
Kakuta, H; Moritani, H; Shikama, H; Ugawa, T | 1 |
Aoyagi, S; Fujii, T; Hiromoto, M; Itoh, S; Matsuzaki, M; Tanaka, M; Toma, Y; Tomochika, Y; Umemoto, S | 1 |
Aihara, N; Hatsushika, S; Kajiyama, G; Mizuno, S; Sagawa, H; Sasaki, H; Sasaki, M; Tao, S; Tazuma, S; Yamashita, G | 1 |
Arbeeny, CM; Bergquist, KE | 1 |
Aihara, N; Hatsushika, S; Mizuno, S; Oya, T; Sagawa, H; Sasaki, H; Sasaki, M; Tazuma, S; Toge, S; Yamashita, G | 1 |
Arai, H; Ishii, K; Kawai, C; Kita, T; Kume, N; Nagano, Y; Otani, H; Ueda, Y; Yokode, M | 1 |
3 review(s) available for pravastatin and Disease Models, Animal
Article | Year |
---|---|
Pravastatin to treat and prevent preeclampsia. Preclinical and clinical studies.
Topics: Animals; Anticholesteremic Agents; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Fetal Development; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Placenta; Pravastatin; Pre-Eclampsia; Pregnancy | 2017 |
Pravastatin for Preventing and Treating Preeclampsia: A Systematic Review.
Topics: Animals; Disease Models, Animal; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Placenta; Placentation; Pravastatin; Pre-Eclampsia; Pregnancy; Randomized Controlled Trials as Topic; Severity of Illness Index | 2018 |
[Systemic treatment for hepatocellular carcinoma].
Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cyclohexanes; Disease Models, Animal; Genetic Therapy; Humans; Immunotherapy; Liver Neoplasms; Meta-Analysis as Topic; Mice; Multicenter Studies as Topic; O-(Chloroacetylcarbamoyl)fumagillol; Octreotide; Pilot Projects; Pravastatin; Primary Prevention; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Sesquiterpenes; Tamoxifen; Thymus Extracts; Time Factors | 2003 |
1 trial(s) available for pravastatin and Disease Models, Animal
Article | Year |
---|---|
Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation.
Topics: Adaptor Proteins, Signal Transducing; Angiotensin II; Animals; Atorvastatin; Biomarkers; Cardiomegaly; Cells, Cultured; Cholesterol; Cholesterol, LDL; Coronary Vessels; Cross-Over Studies; Cytoskeletal Proteins; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrosis; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Guanine Nucleotide Exchange Factors; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Mice; Mice, Knockout; Neuropeptides; Oxidative Stress; Phosphatidylinositol 3-Kinase; Pravastatin; Proto-Oncogene Proteins c-akt; Pyrroles; Quinolines; rac GTP-Binding Proteins; rac1 GTP-Binding Protein; RNA Interference; Signal Transduction; Transfection | 2013 |
133 other study(ies) available for pravastatin and Disease Models, Animal
Article | Year |
---|---|
Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.
Topics: Animals; Biological Transport; Blood-Brain Barrier; Capillaries; Disease Models, Animal; Estrone; Male; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Osteosclerosis; Penicillin G; RNA, Messenger | 2004 |
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.
Topics: Animals; Atorvastatin; Combinatorial Chemistry Techniques; Disease Models, Animal; Fluorobenzenes; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Molecular Structure; Muscle Cells; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Statins alone are ineffective in cerebral malaria but potentiate artesunate.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Atorvastatin; Disease Models, Animal; Drug Synergism; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Malaria, Cerebral; Malaria, Falciparum; Mice; Neuroprotective Agents; Pravastatin; Pyrroles; Simvastatin | 2008 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Pravastatin attenuates sepsis-induced acute lung injury through decreasing pulmonary microvascular permeability via inhibition of Cav-1/eNOS pathway.
Topics: Acute Lung Injury; Animals; Apoptosis; Bronchoalveolar Lavage Fluid; Capillary Permeability; Caveolin 1; Disease Models, Animal; Endothelial Cells; Humans; Male; Mice; Nitric Oxide Synthase Type III; Pravastatin; Pulmonary Alveoli; Sepsis | 2021 |
Gut Microbial Metabolite Pravastatin Attenuates Intestinal Ischemia/Reperfusion Injury Through Promoting IL-13 Release From Type II Innate Lymphoid Cells
Topics: Animals; Disease Models, Animal; Gastrointestinal Microbiome; Humans; Immunity, Innate; Interleukin-1 Receptor-Like 1 Protein; Interleukin-13; Interleukin-33; Intestinal Diseases; Lymphocytes; Male; Mice; Mice, Knockout; Pravastatin; Reperfusion Injury | 2021 |
Metallothionein 2 activation by pravastatin reinforces epithelial integrity and ameliorates radiation-induced enteropathy.
Topics: Animals; Biopsy; Caco-2 Cells; Computational Biology; Disease Models, Animal; Gene Expression Profiling; Gene Expression Regulation; Gene Ontology; Humans; Intestinal Diseases; Intestinal Mucosa; Male; Metallothionein; Mice; Pravastatin; Radiation Injuries; Radiation, Ionizing; Swine; Swine, Miniature; Tight Junctions | 2021 |
Reply: Investigations of pravastatin for the prevention of preeclampsia.
Topics: Animals; Disease Models, Animal; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pre-Eclampsia; Pregnancy; Vascular Endothelial Growth Factor Receptor-1 | 2023 |
Dual-probe molecular MRI for the in vivo characterization of atherosclerosis in a mouse model: Simultaneous assessment of plaque inflammation and extracellular-matrix remodeling.
Topics: Animals; Contrast Media; Diet, High-Fat; Disease Models, Animal; Elastin; Feasibility Studies; Ferrosoferric Oxide; Gadolinium; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; Mice; Mice, Knockout, ApoE; Nitric Oxide; Plaque, Atherosclerotic; Pravastatin; Sensitivity and Specificity | 2019 |
Statins Reverse Postpartum Cardiovascular Dysfunction in a Rat Model of Preeclampsia.
Topics: Animals; Cardiac Output; Cardiovascular Diseases; Disease Models, Animal; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Postpartum Period; Pravastatin; Pre-Eclampsia; Pregnancy; Rats; Rats, Sprague-Dawley; Ventricular Remodeling | 2020 |
Interaction of Oatp1b2 expression and nonalcoholic steatohepatitis on pravastatin plasma clearance.
Topics: Animals; Disease Models, Animal; Gene Dosage; Gene Expression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Metabolic Clearance Rate; Mice, Inbred C57BL; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Pravastatin | 2020 |
Phytoconstituents of an ethanolic pod extract of Prosopis cineraria triggers the inhibition of HMG-CoA reductase and the regression of atherosclerotic plaque in hypercholesterolemic rabbits.
Topics: Animals; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Disease Models, Animal; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Plant Extracts; Plaque, Atherosclerotic; Pravastatin; Prosopis; Rabbits; Triglycerides | 2020 |
Pravastatin Alleviates Radiation Proctitis by Regulating Thrombomodulin in Irradiated Endothelial Cells.
Topics: Animals; Disease Models, Animal; Endothelial Cells; Female; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Leukocytes; Mice; Pravastatin; Proctitis; THP-1 Cells; Thrombomodulin | 2020 |
Identification of therapeutics that target eEF1A2 and upregulate utrophin A translation in dystrophic muscles.
Topics: 5' Untranslated Regions; Animals; Betaxolol; Cell Line; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Internal Ribosome Entry Sites; Mice; Mice, Inbred mdx; Mice, Knockout; Muscular Dystrophy, Duchenne; Myoblasts; Peptide Elongation Factor 1; Pravastatin; Protein Biosynthesis; Up-Regulation; Utrophin | 2020 |
Evaluation of musculoskeletal phenotype of the G608G progeria mouse model with lonafarnib, pravastatin, and zoledronic acid as treatment groups.
Topics: Aging; Animals; Bone and Bones; Bone Density Conservation Agents; Cartilage; Disease Models, Animal; Femur; Glycosaminoglycans; Joints; Lamin Type A; Mice; Mice, Transgenic; Mutation; Osteoarthritis; Phenotype; Piperidines; Pravastatin; Progeria; Protein Processing, Post-Translational; Pyridines; X-Ray Microtomography; Zoledronic Acid | 2020 |
Pravastatin attenuates atherosclerosis after myocardial infarction by inhibiting inflammatory Ly6C
Topics: Animals; Apolipoproteins E; Atherosclerosis; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Plaque, Atherosclerotic; Pravastatin | 2020 |
Sustained Focal Vascular Inflammation Accelerates Atherosclerosis in Remote Arteries.
Topics: Animals; Anti-Inflammatory Agents; Aortitis; Atherosclerosis; Brachiocephalic Trunk; Collagen; Disease Models, Animal; Disease Progression; Inflammation Mediators; Interleukin-6; Lipid Metabolism; Male; Mice, Knockout, ApoE; Minocycline; Necrosis; Plaque, Atherosclerotic; Pravastatin; Time Factors | 2020 |
Statin Effects on Vascular Calcification: Microarchitectural Changes in Aortic Calcium Deposits in Aged Hyperlipidemic Mice.
Topics: Age Factors; Animals; Aorta; Aortic Diseases; Atherosclerosis; Calcium; Disease Models, Animal; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Mice, Inbred C57BL; Mice, Knockout, ApoE; Plaque, Atherosclerotic; Pravastatin; Rupture, Spontaneous; Time Factors; Vascular Calcification | 2021 |
Pravastatin Decreases Infarct Size Induced by Coronary Artery Ischemia/Reperfusion with Elevated eNOS Expression in Rats.
Topics: Animals; Coronary Vessels; Disease Models, Animal; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardium; Nitric Oxide Synthase Type III; Pravastatin; Rats; Rats, Sprague-Dawley; Reperfusion Injury; RNA | 2018 |
Different Effects of Pravastatin on Preeclampsia-like Symptoms in Different Mouse Models.
Topics: Animals; Arterial Pressure; Disease Models, Animal; Female; Male; Mice; Mice, Inbred C57BL; NG-Nitroarginine Methyl Ester; Pravastatin; Pre-Eclampsia; Pregnancy | 2018 |
Pravastatin improves risk factors but not ischaemic tolerance in obese rats.
Topics: Animals; Blood Glucose; Body Weight; Diet, Carbohydrate Loading; Diet, High-Fat; Disease Models, Animal; Heart; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Insulin Resistance; Lipid Peroxidation; Male; Mitochondria; Mitochondrial Dynamics; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Obesity; Pravastatin; Rats; Rats, Wistar; Risk Factors | 2018 |
Effect of the anti-IL-17 antibody on allergic inflammation in an obesity-related asthma model.
Topics: Adiponectin; Adipose Tissue; Animals; Anti-Asthmatic Agents; Antibodies; Asthma; Bronchoconstriction; Diet, High-Fat; Disease Models, Animal; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-17; Leptin; Lung; Mice, Inbred C57BL; Obesity; Pravastatin; Th17 Cells; Th2 Cells | 2018 |
Pravastatin therapy during preeclampsia prevents long-term adverse health effects in mice.
Topics: Animals; Cardiovascular Diseases; Disease Models, Animal; Endothelin-1; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Mice; Mice, Inbred C57BL; Placenta; Pravastatin; Pre-Eclampsia; Pregnancy; Risk Factors; Vascular Remodeling | 2018 |
Pravastatin polarizes the phenotype of macrophages toward M2 and elevates serum cholesterol levels in apolipoprotein E knockout mice.
Topics: Animals; Anticholesteremic Agents; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Cholesterol; Disease Models, Animal; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Phenotype; Plaque, Atherosclerotic; Pravastatin | 2018 |
Pravastatin improves atherosclerosis in mice with hyperlipidemia by inhibiting TREM-1/DAP12.
Topics: Adaptor Proteins, Signal Transducing; Animals; Anticholesteremic Agents; Apolipoproteins E; Atherosclerosis; Disease Models, Animal; Hyperlipidemias; Interleukin-1; Mice; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Pravastatin; Triggering Receptor Expressed on Myeloid Cells-1; Tumor Necrosis Factor-alpha | 2018 |
Placental nitric oxide formation and endothelium-dependent vasodilation underlie pravastatin effects against angiogenic imbalance, hypertension in pregnancy and intrauterine growth restriction.
Topics: Animals; Blood Pressure; Disease Models, Animal; Endothelium, Vascular; Female; Fetal Growth Retardation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pregnancy-Induced; Neovascularization, Physiologic; Nitric Oxide; Oxidative Stress; Placenta; Pravastatin; Pre-Eclampsia; Pregnancy; Rats; Rats, Wistar; Vasodilation | 2019 |
Combination therapy with cilostazol and pravastatin improves antiatherogenic effects in low-density lipoprotein receptor knockout mice.
Topics: Animals; Aorta; Aortic Diseases; Atherosclerosis; Cell Adhesion Molecules; Cholesterol, Dietary; Cilostazol; Cytokines; Diet, High-Fat; Disease Models, Animal; Drug Therapy, Combination; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipids; Male; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Platelet Aggregation Inhibitors; Pravastatin; Receptors, LDL | 2018 |
A Comparison of the Anti-Inflammatory Effects of Four Combined Statin and Antiplatelet Therapies on Tumor Necrosis Factor-Mediated Acute Inflammation in vivo.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Cilostazol; Clopidogrel; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipopolysaccharides; Male; Mice; Platelet Aggregation Inhibitors; Pravastatin; Rosuvastatin Calcium; Treatment Outcome; Tumor Necrosis Factor-alpha | 2019 |
Pravastatin attenuates hypertension, oxidative stress, and angiogenic imbalance in rat model of placental ischemia-induced hypertension.
Topics: Animals; Blood Pressure; Cells, Cultured; Disease Models, Animal; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Ischemia; Neovascularization, Physiologic; Oxidative Stress; Placenta; Pravastatin; Pre-Eclampsia; Pregnancy; Rats; Rats, Sprague-Dawley; Thiobarbituric Acid Reactive Substances; Trophoblasts; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2013 |
Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia.
Topics: Adenoviridae; Animals; Cell Hypoxia; Disease Models, Animal; Endoglin; Female; Gene Expression Regulation; Gene Transfer Techniques; Genetic Vectors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracellular Signaling Peptides and Proteins; Mice; Neovascularization, Physiologic; Placenta; Placenta Growth Factor; Pravastatin; Pre-Eclampsia; Pregnancy; Pregnancy Proteins; RNA, Messenger; Signal Transduction; Time Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2014 |
Increased inducibility of ventricular tachycardia and decreased heart rate variability in a mouse model for type 1 diabetes: effect of pravastatin.
Topics: Animals; Diabetes Mellitus, Type 1; Disease Models, Animal; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Pravastatin; Tachycardia, Ventricular | 2013 |
The effect of maternal pravastatin therapy on adverse sensorimotor outcomes of the offspring in a murine model of preeclampsia.
Topics: Analysis of Variance; Animals; Anticholesteremic Agents; Disease Models, Animal; Female; Fetal Development; Gait Disorders, Neurologic; Humans; Male; Mice; Postural Balance; Pravastatin; Pre-Eclampsia; Pregnancy; Prenatal Exposure Delayed Effects; Psychomotor Disorders; Reflex; Sex Factors; Transduction, Genetic; Vascular Endothelial Growth Factor Receptor-1 | 2014 |
The effect of prenatal pravastatin treatment on altered fetal programming of postnatal growth and metabolic function in a preeclampsia-like murine model.
Topics: Analysis of Variance; Animals; Area Under Curve; Blood Glucose; Body Weight; Cell Cycle Proteins; Disease Models, Animal; Female; Fetal Development; Insulin; Male; Mice; Pravastatin; Pre-Eclampsia; Pregnancy; Receptors, G-Protein-Coupled; Vascular Endothelial Growth Factor Receptor-1 | 2014 |
Pravastatin prevents steroid-induced osteonecrosis in rats by suppressing PPARγ expression and activating Wnt signaling pathway.
Topics: Adipogenesis; Adipose Tissue; Adrenal Cortex Hormones; Animals; beta Catenin; Core Binding Factor Alpha 1 Subunit; Disease Models, Animal; Femur Head; Femur Head Necrosis; Fibrinolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Low Density Lipoprotein Receptor-Related Protein-5; Male; Methylprednisolone; Neovascularization, Physiologic; Osteogenesis; Osteonecrosis; PPAR gamma; Pravastatin; Rats; Rats, Wistar; Wnt Signaling Pathway; Wnt3A Protein | 2014 |
Extravascular optical coherence tomography: evaluation of carotid atherosclerosis and pravastatin therapy.
Topics: Animals; Apolipoproteins E; Carotid Artery Diseases; Carotid Stenosis; Disease Models, Animal; Drug Monitoring; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imaging, Three-Dimensional; Mice; Mice, Inbred C57BL; Mice, Knockout; Pravastatin; Random Allocation; Tomography, Optical Coherence | 2014 |
The anti-inflammatory and antioxidant effects of pravastatin and nebivolol in rat aorta.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Aorta; Ceruloplasmin; Cholesterol; Coronary Artery Disease; Disease Models, Animal; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Nebivolol; NG-Nitroarginine Methyl Ester; Pravastatin; Rats; Rats, Wistar; Triglycerides; Uric Acid | 2014 |
Maternal pravastatin prevents altered fetal brain development in a preeclamptic CD-1 mouse model.
Topics: Animals; Brain; Brain Mapping; Disease Models, Animal; Female; Fetal Development; Fetus; Image Processing, Computer-Assisted; Immunoenzyme Techniques; Magnetic Resonance Imaging; Male; Mice; Pravastatin; Pre-Eclampsia; Pregnancy; Vascular Endothelial Growth Factor Receptor-1 | 2014 |
Melatonin potentiates the anti-tumour effect of pravastatin in rat mammary gland carcinoma model.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Carcinoma in Situ; Carcinoma, Ductal, Breast; Carcinoma, Papillary; Disease Models, Animal; Drug Synergism; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mammary Neoplasms, Experimental; Melatonin; Methylnitrosourea; Pravastatin; Rats, Sprague-Dawley | 2014 |
Ex vivo exposure of bone marrow from chronic kidney disease donor rats to pravastatin limits renal damage in recipient rats with chronic kidney disease.
Topics: Animals; Apoptosis; Blood Pressure; Body Weight; Bone Marrow Cells; Bone Marrow Transplantation; Cell Movement; Chemokine CXCL5; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Glomerular Filtration Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Pravastatin; Rats; Rats, Inbred Lew; Renal Insufficiency, Chronic; Tissue Donors; Transplantation, Homologous | 2015 |
Co-administration of paroxetine increased the systemic exposure of pravastatin in diabetic rats due to the decrease in liver distribution.
Topics: Administration, Intravenous; Administration, Oral; Animals; Body Fluids; Carbamates; Cell Separation; Diabetes Mellitus, Experimental; Diet, High-Fat; Disease Models, Animal; Feces; Hepatocytes; Intestinal Absorption; Liver; Male; Paroxetine; Piperidines; Pravastatin; Rats, Sprague-Dawley; Tissue Distribution | 2015 |
SmgGDS as a Crucial Mediator of the Inhibitory Effects of Statins on Cardiac Hypertrophy and Fibrosis: Novel Mechanism of the Pleiotropic Effects of Statins.
Topics: Adaptor Proteins, Signal Transducing; Animals; Blotting, Western; Cardiomegaly; Cell Proliferation; Cells, Cultured; Chemokines; Cytoskeletal Proteins; Disease Models, Animal; Fibrosis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Myocytes, Cardiac; Pravastatin; Random Allocation; Rats; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Role; Species Specificity | 2016 |
Pravastatin Effects on Placental Prosurvival Molecular Pathways in a Mouse Model of Preeclampsia.
Topics: Animals; Apoptosis; Disease Models, Animal; Female; HSP27 Heat-Shock Proteins; MAP Kinase Signaling System; Mice; Phosphorylation; Placenta; Pravastatin; Pre-Eclampsia; Pregnancy; STAT3 Transcription Factor; Vascular Endothelial Growth Factor Receptor-1 | 2016 |
Pravastatin activates activator protein 2 alpha to augment the angiotensin II-induced abdominal aortic aneurysms.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Animals; Anticholesteremic Agents; Aortic Aneurysm, Abdominal; Apolipoproteins E; Blotting, Western; Cells, Cultured; Disease Models, Animal; Gene Expression Regulation; Humans; Male; Mice; Mice, Knockout; Myocytes, Smooth Muscle; Phosphorylation; Pravastatin; Signal Transduction; Transcription Factor AP-2 | 2017 |
Rejuvenating premature aging.
Topics: Animals; Bone Density Conservation Agents; Cell Nucleus; Diphosphonates; Disease Models, Animal; Drug Therapy, Combination; Farnesyltranstransferase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Lamin Type A; Longevity; Mice; Mice, Knockout; Nuclear Proteins; Pravastatin; Prenylation; Progeria; Protein Precursors; Tumor Suppressor Protein p53; Zoledronic Acid | 2008 |
Multiple effects of HMG-CoA reductase inhibitors (statins) besides their lipid-lowering function.
Topics: Animals; Cholesterol; Disease Models, Animal; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation; Interleukin-6; Kidney; Mice; Pravastatin; Reperfusion Injury | 2008 |
Statin ameliorates hypoxia-induced pulmonary hypertension associated with down-regulated stromal cell-derived factor-1.
Topics: Actins; Animals; Bone Marrow Cells; CD18 Antigens; Cell Differentiation; Cells, Cultured; Chemokine CXCL12; Disease Models, Animal; Down-Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypoxia; Intercellular Adhesion Molecule-1; Mice; Mice, Inbred BALB C; Muscle, Smooth, Vascular; Pravastatin; Proto-Oncogene Proteins c-kit; Receptors, CXCR4; Stem Cells; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Pravastatin improves function in hibernating myocardium by mobilizing CD133+ and cKit+ bone marrow progenitor cells and promoting myocytes to reenter the growth phase of the cardiac cell cycle.
Topics: AC133 Antigen; Animals; Antigens, CD; Bone Marrow Cells; Cell Movement; Cell Proliferation; Coronary Circulation; Coronary Stenosis; Disease Models, Animal; Dose-Response Relationship, Drug; GATA4 Transcription Factor; Glycoproteins; Hemodynamics; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mitosis; Muscle Development; Myocardial Contraction; Myocytes, Cardiac; Peptides; Pravastatin; Proto-Oncogene Proteins c-kit; Regeneration; Stem Cells; Swine | 2009 |
[Effects of pravastatin on myocardial connexin 43, IFN-gamma and IL-10 expressions in a murine model of viral myocarditis induced by Coxsackievirus B3].
Topics: Animals; Connexin 43; Coxsackievirus Infections; Disease Models, Animal; Interferon-gamma; Interleukin-10; Male; Mice; Mice, Inbred BALB C; Myocarditis; Myocardium; Pravastatin | 2008 |
3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension.
Topics: Animals; Atorvastatin; Disease Models, Animal; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Male; Monocrotaline; Phosphodiesterase Inhibitors; Pravastatin; Pulmonary Artery; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2009 |
Pravastatin limits radiation-induced vascular dysfunction in the skin.
Topics: Animals; Blood Vessels; Cell Communication; Chemokine CCL2; Chemokine CXCL1; Disease Models, Animal; E-Selectin; Endothelium, Vascular; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Leukocytes; Male; Mice; Mice, Inbred BALB C; Mice, Knockout; Nitric Oxide; Nitric Oxide Synthase Type III; Pravastatin; Radiodermatitis; Radiotherapy; Skin | 2009 |
Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury.
Topics: Abortion, Spontaneous; Animals; Animals, Newborn; Anticoagulants; Antithrombin III; Cells, Cultured; Disease Models, Animal; Female; Humans; Infant, Newborn; Male; Mice; Monocytes; Nitrogen Oxides; Oxidative Stress; Placenta; Pravastatin; Pregnancy; Protein Binding; Thrombin; Thromboplastin; Trophoblasts; Vascular Endothelial Growth Factor Receptor-1 | 2009 |
Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anticholesteremic Agents; Apolipoprotein A-I; Astrocytes; Chemokine CCL2; Cholesterol; Cognition; Disease Models, Animal; Drug Therapy, Combination; Hippocampus; Interleukin-1beta; Male; Maze Learning; Mice; Mice, Transgenic; Microglia; Plaque, Amyloid; Pravastatin; Protease Nexins; Receptors, Cell Surface; Tumor Necrosis Factor-alpha | 2009 |
Characteristic changes in coronary artery at the early hyperglycaemic stage in a rat type 2 diabetes model and the effects of pravastatin.
Topics: Animals; Coronary Vessels; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Male; Nitric Oxide Synthase Type III; Pravastatin; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Superoxides | 2009 |
Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Cell Survival; Disease Models, Animal; Dopamine; Humans; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neuroglia; Neurons; Neuroprotective Agents; Neurotransmitter Agents; NF-kappa B; Parkinson Disease; Parkinsonian Disorders; Pravastatin; Proto-Oncogene Proteins p21(ras); Simvastatin; Substantia Nigra | 2009 |
Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosis.
Topics: Animals; Apoptosis; Body Weight; Carbon Tetrachloride; Cell Line, Transformed; Disease Models, Animal; Drug Synergism; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver Cirrhosis; Male; Mice; Mice, Inbred BALB C; Mitochondria; Organ Size; Pravastatin; Protein Kinase C; Protein Kinase Inhibitors; Thioacetamide | 2010 |
Low-dosage statins reduce choroidal damage in hypercholesterolemic rabbits.
Topics: Animals; Anticholesteremic Agents; Cholesterol; Cholesterol, Dietary; Choroid; Choroid Diseases; Disease Models, Animal; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Male; Muscle, Smooth, Vascular; Pravastatin; Rabbits; Triglycerides | 2011 |
Effect of olmesartan and pravastatin on experimental cerebral aneurysms in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cerebral Arteries; Circle of Willis; Corrosion Casting; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelial Cells; Hydralazine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Intracranial Aneurysm; Microscopy, Electron, Scanning; Pravastatin; Rats; Tetrazoles; Treatment Outcome; Vasodilator Agents | 2010 |
Mitochondrial K(ATP) channels-derived reactive oxygen species activate pro-survival pathway in pravastatin-induced cardioprotection.
Topics: Animals; Cell Survival; Cells, Cultured; Disease Models, Animal; Heart; Humans; In Vitro Techniques; Male; Myocardial Infarction; Myocytes, Cardiac; Potassium Channels; Pravastatin; Protective Agents; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species | 2010 |
Effect of pravastatin on ventricular arrhythmias in infarcted rats: role of connexin43.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blotting, Western; Bosentan; Cardiac Pacing, Artificial; Connexin 43; Disease Models, Animal; Drug Therapy, Combination; Endothelin Receptor Antagonists; Endothelin-1; Fluorescent Antibody Technique; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Maleimides; Mevalonic Acid; Myocardial Infarction; Myocardium; Pravastatin; Protein Kinase C; Protein Kinase Inhibitors; Rats; Rats, Wistar; Receptors, Endothelin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Time Factors; Ultrasonography | 2010 |
Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis.
Topics: Animals; Apolipoprotein A-I; Apolipoproteins E; Bone Density; Chemokines; Cytokines; Disease Models, Animal; fas Receptor; Female; Immunoglobulin G; Lipids; Lupus Erythematosus, Systemic; Mice; Mice, Inbred C57BL; Mice, Knockout; Peptides; Plaque, Atherosclerotic; Pravastatin | 2010 |
Reduction of endoplasmic reticulum stress--a novel mechanism of action of statins in the protection against atherosclerosis.
Topics: Animals; Antigens, Differentiation; Atherosclerosis; Cell Line; Disease Models, Animal; DNA-Binding Proteins; eIF-2 Kinase; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Eukaryotic Initiation Factor-2; Fatty Acids; Heat-Shock Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Mice; Mice, Knockout; Phosphorylation; Pravastatin; Receptors, LDL; Regulatory Factor X Transcription Factors; Simvastatin; Stress, Physiological; Transcription Factors | 2010 |
Preventive effects of pravastatin on thrombin-triggered vascular responses via Akt/eNOS and RhoA/Rac1 pathways in vivo.
Topics: Animals; Anticholesteremic Agents; Aorta; Coronary Vessels; Disease Models, Animal; Guanosine Triphosphate; Injections, Intravenous; Male; NADPH Oxidases; Nitric Oxide Synthase Type III; Pravastatin; Proto-Oncogene Proteins c-akt; rac1 GTP-Binding Protein; Rats; Rats, Inbred SHR; Rats, Wistar; Reactive Oxygen Species; rhoA GTP-Binding Protein; Signal Transduction; Thrombin; Vasodilation | 2010 |
Effect of pravastatin on bleomycin-induced acute lung injury and pulmonary fibrosis.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Bleomycin; Blotting, Western; Bronchoalveolar Lavage Fluid; Connective Tissue Growth Factor; Cyclin D1; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression; Hydroxyproline; Mice; Mice, Inbred C57BL; Pravastatin; Pulmonary Fibrosis; Respiratory Distress Syndrome; Reverse Transcriptase Polymerase Chain Reaction; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Transforming Growth Factor beta1 | 2010 |
Pravastatin administration does not induce detrimental effects on hemodynamics and collaterals of portal hypertensive rats.
Topics: Animals; Collateral Circulation; Cyclooxygenase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin-1; Enzyme Inhibitors; Hemodynamics; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Portal; Indomethacin; Male; Nitric Oxide Synthase; Nitroarginine; Portal System; Pravastatin; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Time Factors; Vascular Resistance; Vasoconstriction; Vasoconstrictor Agents | 2010 |
A new mouse model to explore therapies for preeclampsia.
Topics: Animals; Blood Pressure; Disease Models, Animal; Female; Leptin; Mice; Mice, Inbred CBA; Mice, Inbred DBA; Pravastatin; Pre-Eclampsia; Pregnancy; Pregnancy Outcome; Vascular Endothelial Growth Factor A | 2010 |
Influence of long-term treatment with pravastatin on the survival, evolution of cutaneous lesion and weight of animals infected by Leishmania amazonensis.
Topics: Analysis of Variance; Animals; Antiprotozoal Agents; Body Weight; Cricetinae; Disease Models, Animal; Disease Susceptibility; Dose-Response Relationship, Drug; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leishmania mexicana; Leishmaniasis, Cutaneous; Male; Mesocricetus; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pravastatin; Statistics, Nonparametric; Survival Rate | 2011 |
Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model.
Topics: Animals; Animals, Newborn; Cell Line; Disease Models, Animal; Female; HEK293 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intraperitoneal; Lentivirus; Male; Mice; Mice, Transgenic; Placenta; Placenta Growth Factor; Pravastatin; Pre-Eclampsia; Pregnancy; Pregnancy Proteins; Transduction, Genetic; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
Preeclampsia: animal models for a human cure.
Topics: Animals; Animals, Newborn; Disease Models, Animal; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lentivirus; Male; Mice; Mice, Transgenic; Placenta; Placenta Growth Factor; Pravastatin; Pre-Eclampsia; Pregnancy; Pregnancy Proteins; Transduction, Genetic; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
Pravastatin modulates liver bile acid and cholesterol homeostasis in rats with chronic cholestasis.
Topics: Animals; Bile Acids and Salts; Cholestasis; Cholesterol; Chronic Disease; Disease Models, Animal; Gene Expression Regulation, Enzymologic; Homeostasis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Membrane Transport Proteins; Permeability; Pravastatin; Rats; Rats, Wistar; RNA, Messenger; Time Factors; Transcription Factors | 2011 |
Statins promote the growth of experimentally induced cerebral aneurysms in estrogen-deficient rats.
Topics: Animals; Apoptosis; Brain; Cells, Cultured; Disease Models, Animal; Endothelial Cells; Estrogens; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Intracranial Aneurysm; Nitric Oxide Synthase Type III; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin | 2011 |
The neuroprotective effect of two statins: simvastatin and pravastatin on a streptozotocin-induced model of Alzheimer's disease in rats.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neuroprotective Agents; Pravastatin; Rats; Rats, Wistar; Simvastatin; Streptozocin | 2011 |
Pravastatin for thioacetamide-induced hepatic failure and encephalopathy.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Disease Models, Animal; Hepatic Encephalopathy; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Failure, Acute; Male; Nitric Oxide; Nitric Oxide Synthase; Pravastatin; Rats; Rats, Sprague-Dawley; Thioacetamide | 2012 |
Role of complement component C1q in the onset of preeclampsia in mice.
Topics: Animals; Blood Pressure; Cell Movement; Collagenases; Complement C1q; Disease Models, Animal; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Knockout; Placenta; Pravastatin; Pre-Eclampsia; Pregnancy; Regional Blood Flow; Trophoblasts; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
Pravastatin reduces Marfan aortic dilation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Diseases; Dilatation, Pathologic; Disease Models, Animal; Elastin; Endoplasmic Reticulum; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Losartan; Male; Marfan Syndrome; Mice; Mice, Mutant Strains; Muscle, Smooth, Vascular; Pravastatin; Treatment Outcome; Tunica Media | 2011 |
Modification of hepatic iron metabolism induced by pravastatin during obstructive cholestasis in rats.
Topics: Animals; Antimicrobial Cationic Peptides; Cation Transport Proteins; Cholestasis; Disease Models, Animal; Gene Expression Regulation; Heme Oxygenase-1; Hepcidins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iron; Liver; Male; Pravastatin; Rats; Rats, Wistar | 2011 |
Pravastatin inhibits farnesol production in Candida albicans and improves survival in a mouse model of systemic candidiasis.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Colony Count, Microbial; Disease Models, Animal; Farnesol; Female; Mice; Mice, Inbred C3H; Pravastatin; Survival Analysis; Virulence Factors | 2012 |
Effects of pravastatin on mediators of vascular function in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia.
Topics: Animals; Disease Models, Animal; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Pravastatin; Pre-Eclampsia; Pregnancy; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
HMG-CoA reductase inhibitors (statins) reduce hypertrophic scar formation in a rabbit ear wounding model.
Topics: Animals; Cicatrix, Hypertrophic; Disease Models, Animal; Ear; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Rabbits; Simvastatin; Wound Healing | 2012 |
Pravastatin reduces steroid-induced osteonecrosis of the femoral head in SHRSP rats.
Topics: Adipocytes; Animals; Anti-Inflammatory Agents; Bone Marrow; Disease Models, Animal; Drinking Water; Femur Head Necrosis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Lipid Metabolism; Male; Methylprednisolone; Methylprednisolone Acetate; Oxidative Stress; Pravastatin; Rats; Rats, Inbred SHR | 2012 |
Short-term statin administration in hypercholesterolaemic rabbits resistant to postconditioning: effects on infarct size, endothelial nitric oxide synthase, and nitro-oxidative stress.
Topics: Animals; Anticholesteremic Agents; Disease Models, Animal; Hypercholesterolemia; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Pravastatin; Proto-Oncogene Proteins c-akt; Rabbits; Simvastatin | 2012 |
Pravastatin normalizes ET-1-induced contraction in the aorta of type 2 diabetic OLETF rats by suppressing the KSR1/ERK complex.
Topics: Animals; Aorta, Thoracic; Aortic Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin-1; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Pravastatin; Protein Kinases; Protein Phosphatase 2; Rats; Rats, Inbred OLETF; Signal Transduction; src-Family Kinases; Time Factors; Vasoconstriction; Vasoconstrictor Agents | 2012 |
Can statins reduce the inflammatory response associated with preterm birth in an animal model?
Topics: Animals; Disease Models, Animal; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mice; Pravastatin; Pregnancy; Premature Birth; Simvastatin | 2012 |
Pravastatin inhibits plaque rupture and subsequent thrombus formation in atherosclerotic rabbits with hyperlipidemia.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anticholesteremic Agents; Aorta; Aorta, Abdominal; Atherosclerosis; Cholesterol; Cholesterol, LDL; Diet, High-Fat; Disease Models, Animal; Histamine; Hyperlipidemias; Male; Plaque, Atherosclerotic; Pravastatin; Rabbits; Thrombosis; Thromboxane B2; Triglycerides; Viper Venoms | 2013 |
Protective effect of pravastatin on lipopolysaccharide-induced acute lung injury during neutropenia recovery in mice.
Topics: Acute Lung Injury; Animals; Bronchoalveolar Lavage Fluid; Cyclophosphamide; Disease Models, Animal; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Interleukin-1beta; Interleukin-6; Lipopolysaccharides; Mice; Mice, Inbred ICR; Neutropenia; NF-kappa B; Pravastatin; Pulmonary Edema; Respiratory Distress Syndrome; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2013 |
The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis.
Topics: Animals; Cell Adhesion Molecules; Cell Membrane Permeability; Cholesterol; Colitis; Dextran Sulfate; Disease Models, Animal; Enzyme Inhibitors; Epithelial Cells; Gene Expression; Hydroxymethylglutaryl CoA Reductases; Immunoglobulins; Immunohistochemistry; Inflammation; Mice; Mice, Inbred C57BL; Mice, Knockout; Mucoproteins; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Pravastatin; RNA, Messenger | 2003 |
Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin.
Topics: Administration, Oral; Animals; Atorvastatin; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Glucose; Glucose Tolerance Test; Heptanoic Acids; Injections, Intravenous; Insulin; Insulin Secretion; Male; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Streptozocin; Time Factors | 2003 |
Pravastatin decreases cold ischemia--but not alloantigen-dependent transplant arteriosclerosis.
Topics: Animals; Aorta, Abdominal; Arteriosclerosis; Cold Temperature; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Isoantigens; Male; Pravastatin; Rats; Rats, Inbred BN; Rats, Inbred Lew; Transplantation, Homologous; Transplantation, Isogeneic; Tunica Intima | 2003 |
Comparison of urinary excretion of pravastatin and temocapril in bile duct-ligated rats and Eisai hyperbilirubinemic rats (EHBR).
Topics: Animals; Bile Ducts; Cholestasis; Disease Models, Animal; Hyperbilirubinemia; Male; Pravastatin; Rats; Rats, Sprague-Dawley; Thiazepines | 2004 |
Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model.
Topics: Animals; Blood Glucose; Chemokine CCL2; Cholesterol; Diabetes Mellitus, Type 2; Disease Models, Animal; DNA Primers; Glucose Tolerance Test; Hydroxymethylglutaryl CoA Reductases; Immunohistochemistry; Insulin; Leptin; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pravastatin; Rats; Rats, Inbred OLETF; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor beta; Transforming Growth Factor beta1; Triglycerides; Tumor Necrosis Factor-alpha; Ventricular Remodeling | 2004 |
Effect of pravastatin on left ventricular mass by activation of myocardial K ATP channels in hypercholesterolemic rabbits.
Topics: Adenosine Triphosphate; Animals; Anticholesteremic Agents; Disease Models, Animal; Heart; Hypercholesterolemia; Hypertrophy, Left Ventricular; Male; Potassium Channels; Pravastatin; Rabbits | 2004 |
Eisai hyperbilirubinemic rat (EHBR) as an animal model affording high drug-exposure in toxicity studies on organic anions.
Topics: Animals; Anions; Area Under Curve; ATP-Binding Cassette Transporters; Blood Proteins; Creatine Kinase; Disease Models, Animal; Folic Acid Antagonists; Half-Life; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperbilirubinemia; Male; Methotrexate; Muscle, Skeletal; Pravastatin; Protein Binding; Rats; Rats, Inbred Strains; Toxicity Tests; Weight Gain | 2004 |
Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease.
Topics: Animals; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Glomerular Filtration Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pravastatin; Proteinuria; Rats; Rats, Sprague-Dawley; Renal Circulation; Renal Insufficiency; Triglycerides; Urine | 2005 |
Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporine-induced nephropathy.
Topics: Animals; C-Reactive Protein; Cyclosporine; Disease Models, Animal; Fibrosis; Inflammation; Kidney; Kidney Diseases; Losartan; Male; Pravastatin; Rats; Rats, Sprague-Dawley | 2005 |
A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression.
Topics: Animals; Blood Platelets; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Inhibitory Concentration 50; Leukocytes, Mononuclear; Macrophages, Peritoneal; Male; Mice; Nitrates; Nitric Oxide; Nitric Oxide Donors; Nitrites; Nitro Compounds; P-Selectin; Platelet Adhesiveness; Platelet Aggregation; Pravastatin; Pulmonary Embolism; RNA, Messenger; Spleen; Thromboplastin | 2005 |
Hydrophilic statin suppresses vein graft intimal hyperplasia via endothelial cell-tropic Rho-kinase inhibition.
Topics: Animals; Biopsy, Needle; Cell Proliferation; Disease Models, Animal; Graft Rejection; Graft Survival; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperplasia; Immunohistochemistry; In Situ Nick-End Labeling; In Vitro Techniques; Intracellular Signaling Peptides and Proteins; Jugular Veins; Male; Pravastatin; Preoperative Care; Probability; Protein Serine-Threonine Kinases; Rabbits; Random Allocation; Reference Values; rho-Associated Kinases; Risk Factors; Sensitivity and Specificity; Tunica Intima; Vascular Surgical Procedures | 2005 |
Improving effect of ethyl eicosapentanoate on statin-induced rhabdomyolysis in Eisai hyperbilirubinemic rats.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Eicosapentaenoic Acid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperbilirubinemia; Muscle, Skeletal; Platelet Aggregation Inhibitors; Pravastatin; Rats; Rhabdomyolysis; Severity of Illness Index; Treatment Outcome | 2006 |
[The effects of pravastatin on platelet-derived nitric oxide system in rabbits].
Topics: Animals; Atherosclerosis; Blood Platelets; Disease Models, Animal; Male; Nitric Oxide; Nitric Oxide Synthase; Pravastatin; Rabbits; RNA, Messenger | 2005 |
[Therapeutic effects of pravastatin on colitis induced by acetic acid and relevant mechanism: experiment with rats].
Topics: Acetic Acid; Animals; Colitis, Ulcerative; Colon; Disease Models, Animal; Male; Malondialdehyde; Nitric Oxide; Pravastatin; Rats; Rats, Sprague-Dawley; Superoxide Dismutase | 2006 |
Pravastatin reduces microvascular basal lamina damage following focal cerebral ischemia and reperfusion.
Topics: Animals; Basement Membrane; Biomarkers; Blood-Brain Barrier; Cerebral Arterial Diseases; Cerebral Arteries; Cerebral Infarction; Collagen Type IV; Disease Models, Animal; Down-Regulation; Hemoglobins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperemia; Ischemic Attack, Transient; Male; Microcirculation; Pravastatin; Rats; Rats, Wistar; Reperfusion Injury | 2006 |
Pravastatin prevents ischemia-reperfusion injury in rat sciatic nerve.
Topics: Animals; Axons; Cytoprotection; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Male; Neuroprotective Agents; Oxidative Stress; Peripheral Nerves; Pravastatin; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Sciatic Neuropathy; Time Factors; Treatment Outcome; Wallerian Degeneration | 2006 |
Pravastatin reverses the down-regulating effect of inflammation on beta-adrenergic receptors: a disease-drug interaction between inflammation, pravastatin, and propranolol.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Inflammatory Agents; Biological Availability; C-Reactive Protein; Disease Models, Animal; Down-Regulation; Drug Interactions; Electrocardiography; Heart Conduction System; Heart Rate; Inflammation; Interferon-gamma; Interleukin-10; Male; Mycobacterium; Nitrites; Pravastatin; Propranolol; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, beta; Time Factors | 2007 |
Effects of pravastatin in murine collagen-induced arthritis.
Topics: Animals; Arthritis, Experimental; Aspartate Aminotransferases; Blood Urea Nitrogen; Chemokine CCL2; Chemokines; Collagen Type II; Corticosterone; Creatine Kinase; Creatinine; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Male; Mice; Mice, Inbred DBA; Pravastatin; RNA, Messenger; Synovial Membrane | 2007 |
Pravastatin enhances beneficial effects of olmesartan on vascular injury of salt-sensitive hypertensive rats, via pleiotropic effects.
Topics: Animals; Disease Models, Animal; Drug Interactions; Drug Therapy, Combination; Endothelium, Vascular; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Imidazoles; Nitric Oxide; Oxidation-Reduction; Oxidative Stress; Pravastatin; Rats; Rats, Inbred Dahl; Reference Values; Risk Factors; Sensitivity and Specificity; Sodium Chloride, Dietary; Tetrazoles; Vascular Diseases | 2007 |
Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes.
Topics: Adiponectin; Adipose Tissue; Animals; Anticholesteremic Agents; Atorvastatin; Chemokine CCL2; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulation; Glucose; Heptanoic Acids; Hypertriglyceridemia; Insulin Resistance; Leptin; Myocardium; Nitric Oxide; Nitric Oxide Synthase Type III; Pravastatin; Pyrroles; Rats; Rats, Long-Evans; Rats, Mutant Strains; RNA, Messenger; Transforming Growth Factor beta1; Ventricular Dysfunction, Left | 2007 |
Comparison of the antiatherosclerotic effects of dihydropyridine calcium channel blocker and HMG-CoA reductase inhibitor on hypercholesterolemic rabbits.
Topics: Animals; Aorta, Thoracic; Atherosclerosis; Calcium Channel Blockers; Cholesterol; Dihydropyridines; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperplasia; Male; Pravastatin; Rabbits; RNA, Messenger; Scavenger Receptors, Class E; Time Factors; Tunica Intima; Up-Regulation; Vascular Cell Adhesion Molecule-1; Vasodilation | 2007 |
Effect of pravastatin on the development of diabetes and adiponectin production.
Topics: Adipocytes; Adiponectin; Animals; Diabetes Mellitus; Disease Models, Animal; Glucose; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Obesity; Pravastatin | 2008 |
Anti-inflammatory effects of pravastatin on Helicobacter pylori-induced gastritis in mice.
Topics: Animals; Biomarkers; Disease Models, Animal; Female; Follow-Up Studies; Gastric Mucosa; Gastritis; Gene Expression; Helicobacter Infections; Helicobacter pylori; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interleukin-1beta; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase Type III; Pravastatin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Treatment Outcome; Tumor Necrosis Factor-alpha | 2007 |
Effects of Pravastatin on neuroprotection and neurogenesis after cerebral ischemia in rats.
Topics: Animals; Brain Ischemia; Bromodeoxyuridine; Cell Count; Cell Proliferation; Disease Models, Animal; Doublecortin Domain Proteins; Doublecortin Protein; Male; Microtubule-Associated Proteins; Neurologic Examination; Neurons; Neuropeptides; Neuroprotective Agents; Phosphopyruvate Hydratase; Pravastatin; Rats; Rats, Wistar; Time Factors | 2007 |
Effect of pravastatin on sympathetic reinnervation in postinfarcted rats.
Topics: Animals; Blotting, Western; Cardiac Pacing, Artificial; Coronary Vessels; Disease Models, Animal; GAP-43 Protein; Glyburide; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; KATP Channels; Ligation; Male; Myocardial Infarction; Myocardium; Neurofilament Proteins; Nicorandil; Norepinephrine; Pinacidil; Polymerase Chain Reaction; Potassium Channel Blockers; Pravastatin; Rats; Rats, Wistar; RNA, Messenger; Sympathetic Nervous System; Tachycardia, Ventricular; Time Factors; Tyrosine 3-Monooxygenase; Ventricular Fibrillation; Ventricular Remodeling | 2007 |
Pravastatin reduces myocardial infarct size via increasing protein kinase C-dependent nitric oxide, decreasing oxyradicals and opening the mitochondrial adenosine triphosphate-sensitive potassium channels in rabbits.
Topics: Animals; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Preconditioning, Myocardial; KATP Channels; Male; Mitochondria, Heart; Myocardial Infarction; Nitric Oxide; Pravastatin; Protein Kinase C; Rabbits; Reactive Oxygen Species; Superoxides | 2007 |
Statin reverses reduction of adiponectin receptor expression in infarcted heart and in TNF-alpha-treated cardiomyocytes in association with improved glucose uptake.
Topics: Acetylcysteine; Adiponectin; Administration, Oral; Animals; Animals, Newborn; Antioxidants; Blood Glucose; Cells, Cultured; Coronary Vessels; Disease Models, Animal; Dose-Response Relationship, Drug; Fatty Acids; Glucose; Hydrogen Peroxide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Ligation; Lipids; Male; Mice; Myocardial Infarction; Myocardium; Myocytes, Cardiac; Oxidation-Reduction; Pravastatin; Rats; Rats, Sprague-Dawley; Receptors, Adiponectin; Recombinant Proteins; RNA Interference; RNA, Messenger; RNA, Small Interfering; Time Factors; Tumor Necrosis Factor-alpha | 2007 |
Postischemic administration of HMG CoA reductase inhibitor inhibits infarct expansion after transient middle cerebral artery occlusion.
Topics: Animals; Brain; Brain Ischemia; Disease Models, Animal; Drug Administration Schedule; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Middle Cerebral Artery; Male; Pravastatin; Rats; Rats, Wistar | 2007 |
A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo.
Topics: Anabolic Agents; Animals; Animals, Newborn; Bone and Bones; Bone Resorption; Cells, Cultured; Disease Models, Animal; Female; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Inbred BALB C; Osteoclasts; Osteoporosis; Ovariectomy; Pravastatin; Protein Prenylation; Pyridines; Rabbits; rap1 GTP-Binding Proteins; Signal Transduction; Simvastatin; Water | 2007 |
Down-regulation of intestinal multidrug resistance-associated protein 2 in long-evans cinnamon rats.
Topics: Animals; ATP-Binding Cassette Transporters; Disease Models, Animal; Down-Regulation; Hepatolenticular Degeneration; Jejunum; Male; Mannitol; Pravastatin; Probenecid; Rats; Rats, Inbred LEC; Rats, Wistar; RNA, Messenger; Species Specificity; Sulfobromophthalein | 2007 |
Pravastatin attenuates left ventricular remodeling and diastolic dysfunction in angiotensin II-induced hypertensive mice.
Topics: Angiotensin II; Animals; Blood Pressure; Cholesterol; Disease Models, Animal; Fibrosis; Gene Expression Regulation; Heart Failure, Diastolic; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Male; Mice; Mice, Inbred C57BL; Pravastatin; rho-Associated Kinases; Ventricular Remodeling | 2008 |
Regulation of apolipoprotein B secretion in hepatocytes from Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia.
Topics: Animals; Apolipoproteins B; Cells, Cultured; Cholesterol Esters; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Liver; Male; Pravastatin; Rabbits; Receptors, LDL | 1995 |
The mechanism of comparable serum cholesterol lowering effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A inhibitor, between once- and twice-daily treatment regimens in beagle dogs and rabbits.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Anticholesteremic Agents; Binding, Competitive; Cells, Cultured; Cholesterol; Disease Models, Animal; Dogs; Drug Administration Schedule; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; Iodine Radioisotopes; Isotope Labeling; Liver; Male; Pravastatin; Rabbits; Receptors, LDL; Species Specificity; Up-Regulation | 1996 |
Effects of chronic combined treatment with captopril and pravastatin on the progression of insulin resistance and cardiovascular alterations in an experimental model of obesity in dogs.
Topics: Animals; Anticholesteremic Agents; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Captopril; Cardiovascular Diseases; Cholesterol; Coronary Vessels; Disease Models, Animal; Disease Progression; Dogs; Drug Therapy, Combination; Heart; Insulin; Insulin Resistance; Linear Models; Male; Multivariate Analysis; Myocardium; Obesity; Pravastatin; Triglycerides | 1998 |
Atherosclerosis in Marek's disease virus infected hypercholesterolemic roosters is reduced by HMGCoA reductase and ACE inhibitor therapy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arteriosclerosis; Carotid Arteries; Chickens; Cholesterol; Disease Models, Animal; Herpesvirus 2, Gallid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Isoquinolines; Lymphocytes; Marek Disease; Pravastatin; Quinapril; Tetrahydroisoquinolines | 1998 |
Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Blood Glucose; Cholesterol, LDL; Chromans; Coronary Vessels; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Glucose Tolerance Test; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperinsulinism; Hyperlipoproteinemia Type II; Hypoglycemic Agents; Insulin Resistance; Male; Pravastatin; Rabbits; Thiazoles; Thiazolidinediones; Troglitazone; Xanthomatosis | 1999 |
Pravastatin restored the infarct size-limiting effect of ischemic preconditioning blunted by hypercholesterolemia in the rabbit model of myocardial infarction.
Topics: 5'-Nucleotidase; Animals; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Heart Ventricles; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Pravastatin; Rabbits; Treatment Outcome; Triglycerides | 1999 |
Effects of lovastatin and pravastatin on the survival of hamsters with inherited cardiomyopathy.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Cardiomyopathies; Cricetinae; Disease Models, Animal; Female; Lovastatin; Male; Pravastatin; Sex Factors; Survival Analysis; Ubiquinone | 2000 |
Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction.
Topics: Actins; Animals; Cholesterol; Disease Models, Animal; Fatty Acids, Monounsaturated; Fibrosis; Fluvastatin; Gene Expression; Glycation End Products, Advanced; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney; Membrane Proteins; Mice; Nephritis, Interstitial; Oxidative Stress; Pravastatin; RNA, Messenger; Triglycerides; Ureteral Obstruction | 2001 |
Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site.
Topics: Allosteric Site; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion; Disease Models, Animal; Drug Design; Humans; Integrin alpha4beta1; Integrins; Intercellular Adhesion Molecule-1; Lovastatin; Lymphocyte Activation; Lymphocyte Function-Associated Antigen-1; Macrophage-1 Antigen; Mice; Models, Molecular; Molecular Structure; Mutagenesis, Site-Directed; Naphthalenes; Peritonitis; Pravastatin; Protein Binding; Receptors, Lymphocyte Homing; T-Lymphocytes | 2001 |
Pravastatin reduces myocardial lesions induced by acute inhibition of nitric oxide biosynthesis in normocholesterolemic rats.
Topics: Analysis of Variance; Animals; Anticholesteremic Agents; Cardiomyopathies; Disease Models, Animal; Endothelium, Vascular; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Necrosis; NG-Nitroarginine Methyl Ester; Nitrates; Nitric Oxide Synthase; Nitrites; Pravastatin; Rats; Rats, Wistar; Thromboxane B2 | 2001 |
Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis.
Topics: Animals; Anti-Inflammatory Agents; Arteriosclerosis; Blood Pressure; Chemokine CCL2; Coronary Vessels; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Lipids; Macrophages; Male; Monocytes; NG-Nitroarginine Methyl Ester; Nitrates; Nitric Oxide Synthase; Nitrites; Nitroarginine; Peptidyl-Dipeptidase A; Pravastatin; Proliferating Cell Nuclear Antigen; Pyridines; Rats; Rats, Inbred WKY; rhoA GTP-Binding Protein; RNA, Messenger; Systole; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2001 |
Stability of atheromatous plaque affected by lesional composition: study of WHHL rabbits treated with statins.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Disease Models, Animal; Fatty Acids, Monounsaturated; Fluvastatin; Indoles; Lipids; Pravastatin; Rabbits | 2001 |
Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model.
Topics: Animals; Anticholesteremic Agents; Cholesterol; Cricetinae; Dietary Fats; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Induction; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mesocricetus; Pravastatin; Quinuclidines | 2002 |
Importance of NAD(P)H oxidase-mediated oxidative stress and contractile type smooth muscle myosin heavy chain SM2 at the early stage of atherosclerosis.
Topics: Actins; Animals; Anticholesteremic Agents; Antioxidants; Aorta, Thoracic; Arteriosclerosis; Cholesterol; Diet, Atherogenic; Disease Models, Animal; Elasticity; Hypercholesterolemia; Male; Membrane Transport Proteins; Muscle, Smooth, Vascular; Myosin Heavy Chains; NADH, NADPH Oxidoreductases; NADPH Dehydrogenase; NADPH Oxidases; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Oxidative Stress; Phosphoproteins; Pravastatin; Probucol; Protein Isoforms; Rabbits; Smooth Muscle Myosins; Superoxides | 2002 |
Inhibitory effects of pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in prairie dogs.
Topics: Animals; Bile; Bile Acids and Salts; Cholelithiasis; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Phospholipids; Pravastatin; Sciuridae | 1992 |
The effect of pravastatin on serum cholesterol levels in hypercholesterolemic diabetic rabbits.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins; Body Weight; Cholesterol; Coconut Oil; Diabetes Complications; Diabetes Mellitus; Diet, Atherogenic; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Naphthalenes; Plant Oils; Pravastatin; Rabbits; Triglycerides | 1991 |
[Effects of a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase on cholesterol gallstone formation in prairie dogs].
Topics: Animals; Cholelithiasis; Cholesterol; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Sciuridae | 1991 |
Lipoproteins and atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholesterol Esters; Cholestyramine Resin; Disease Models, Animal; Foam Cells; Heptanoic Acids; Hyperlipidemia, Familial Combined; Lipoproteins, LDL; Liver; Macrophages; Mice; Naphthalenes; Pravastatin; Probucol; Rabbits; Receptors, Cell Surface; Receptors, Lipoprotein | 1990 |